News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Studies Highlight The Potential Of Liraglutide, Novo Nordisk’s Investigational GLP-1 Analogue
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Long-Acting Analogue Offers Improved Blood Glucose Control, Weight Control and Low Risk of Hypoglycaemia, in a Once-Daily Treatment
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Novo Nordisk
MORE ON THIS TOPIC
Drug development
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
April 7, 2026
·
2 min read
·
Annalee Armstrong
Immunology and inflammation
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
April 7, 2026
·
3 min read
·
Tristan Manalac
Pipeline
Pharma Pipeline Stalls for First Time in Decades: Citeline
April 6, 2026
·
2 min read
·
Tristan Manalac
Insights
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
April 6, 2026
·
4 min read
·
Jennifer C. Smith-Parker
